CLINICAL TRIALS

OncoPep is advancing PVX-410 into multiple single agent and combination therapy clinical trials to address the unmet medical need in smoldering multiple myeloma and triple negative breast cancer.

 

clinical-trials-dade.jpg

Smoldering Multiple Myeloma Trials

PVX-410 + durvalumab (#NCT02886065)

This Phase 1b investigator sponsored research study is evaluating the combination of PVX-410 with the checkpoint antibody durvalumab (Celgene, Inc.) to test the safety of an investigational intervention and also to define the appropriate dosing to use for further studies.

Durvalumab is an inhibitor of the immune checkpoint programmed death ligand 1 (PD-L1), which is being combined here to further augment the immune activity of PVX-410. The combination with durvalumab is a 3 arm study (durvalumab alone, n=3, PVX-410 plus durvalumab, n=10, and PVX-410 plus durvalumab plus lenalidomide, n=10) and is currently enrolling patients at Massachusetts General Hospital (Boston).

 
Screen Shot 2017-11-09 at 2.28.43 PM.png

Triple Negative Breast Cancer Trials

PVX-410 + durvalumab (#NCT02826434)

The purpose of this investigator sponsored research study is to evaluate checkpoint-mediated immunotherapy with a peptide vaccine (PVX-410) and the programmed death ligand 1 (PD-L1) inhibitor, durvalumab (AstraZeneca, Inc.), as a possible adjuvant treatment for non-metastatic (Stage II/II) triple negative breast cancer. This research study is studying the safety, tolerability, and immune response of this investigational combination.

Treatment centers currently enrolling patients include the cancer centers at Massachusetts General Hospital (Boston), Dana Farber Cancer Institute (Boston), Beth Israel Deaconess Hospital (Boston), Moffitt Cancer Center (Tampa), and New York University (New York).
 

PVX-410 + pembrolizumab (#NCT03362060)

The purpose of this investigator sponsored research study is to evaluate checkpoint-mediated immunotherapy with a peptide vaccine (PVX-410) and programmed cell death protein 1 (PD-1) inhibitor, pembrolizumab (Merck, Inc.), as a possible adjuvant treatment for metastatic triple negative breast cancer. This research study is studying the safety, tolerability, and immune response of this investigational combination.

More information on the studies of PVX-410 can be found at www.clinicaltrials.gov.

 
trip-neg-banner.jpg